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Abstract: Endothelial dysfunction worsens when body mass index (BMI) increases. Pannexin1 
(Panx1) ATP release channels regulate endothelial function and lipid homeostasis in mice. We 
investigated whether the Panx1-400A>C single nucleotide polymorphism (SNP), encoding for a 
gain-of-function channel, associates with endothelial dysfunction in non-obese and obese 
individuals. Myocardial blood flow (MBF) was measured by 13N-ammonia positron 
emission/computed tomography at rest, during cold pressor test (CPT) or dipyridamole-induced 
hyperemia. Myocardial flow reserve (MFR) and endothelial function were compared in 43 
non-obese (BMI < 30 kg/m2) vs. 29 obese (BMI ≥ 30 kg/m2) participants and genotyping for the 
Panx1-400A>C SNP was performed. Groups comprised subjects homozygous for the C allele (n = 
40) vs. subjects with at least one A allele (n = 32). MBF (during CPT or hyperemia), MFR and 
endothelial function correlated negatively with BMI in the full cohort. BMI correlated negatively 
with MFR and endothelial function in non-obese Panx1-400C subjects, but not in Panx1-400A 
individuals nor in obese groups. BMI correlated positively with serum triglycerides, insulin or 
HOMA. MFR correlated negatively with these factors in non-obese Panx1-400C but not in 
Panx1-400A individuals. Here, we demonstrated that Panx1-400C SNP predisposes to 
BMI-dependent endothelial dysfunction in non-obese subjects. This effect may be masked by 
excessive dysregulation of metabolic factors in obese individuals. 
Keywords: Panx1; polymorphism; endothelial function; obesity 
 
1. Introduction 
Endothelial dysfunction, the main cause of coronary artery disease, aggravates with increasing 
bodyweight and obesity [1]. A possible role for ATP in the process of endothelial dysfunction is still 
a matter of debate. Extracellular nucleotides, such as ATP, generally display vasculoprotective 
properties by regulating vasodilation through nitric oxide production [2,3]. However, ATP has also 
been shown to participate to the onset of endothelial dysfunction through the activation of P2X4 and 
P2X7 purinergic receptors [4]. In fact, prolonged exposure of endothelial cells to ATP enhances the 
expression of chemokines and adhesion molecules by endothelial cells [4,5]. Pannexin1 (Panx1) 
channels are newly discovered ATP release channels that are increasingly recognized to critically 
regulate vascular function [6]. Panx1 is expressed in most cells of the body, including diverse types 
of blood cells, endothelial and smooth muscle cells but also adipocytes [7,8]. ATP released through 
Panx1 channels can target surface receptors in a paracrine or autocrine fashion allowing for 
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intercellular signaling and tissue homeostasis. Panx1 channels are activated under specific 
conditions such as mechanical stretch, elevated extracellular potassium or metabotropic (P2Y) or 
ionotropic (P2X) receptor activation, resulting in the elevation of intracellular calcium. Studies 
performed in mice have revealed a key role for Panx1 channels in the regulation of endothelial 
function as well as for lipid homeostasis. Thus, Panx1 has been shown to facilitate 
endothelium-dependent vasodilation in large arteries [9]. During acute inflammation, Panx1 
channels in the endothelium promote leukocyte adhesion and emigration through the vascular wall 
[10,11]. Moreover, Panx1 deficiency has been shown to be associated with atherosclerosis and white 
adipose tissue accumulation as well as with lymphatic dysfunction [12]. In mice, Panx1 appeared to 
control adipose stromal cell proliferation and differentiation, thereby regulating fat accumulation in 
vivo [13]. Interestingly, a Panx1-400A>C single nucleotide polymorphism (SNP; rs1138800), 
inducing an amino acid change from a Glutamine to a Histidine (Q5H) in the N-terminus of Panx1, 
encodes for a gain-of-function channel [14]. The Panx1-400C genetic variant, encoding for the 
gain-of-function channel, specifically enhanced collagen-induced ATP release and platelet 
aggregation [14]. Although multiple studies in mice point to a role for Panx1 in vascular pathologies 
caused by impaired endothelial function, whether the Panx1-400A>C SNP associates with 
endothelial dysfunction in humans is presently unknown. 
2. Materials and Methods 
2.1. Study Population 
Study participants have been recruited at the Geneva University Hospitals by flyers and 
newspaper advertisements. The study was approved by the institutional review board of the Geneva 
University Hospitals (No. 07-183) [15,16]. Each participant signed an approved informed consent 
form. Study participants underwent an initial screening visit comprising physical examination, 
electrocardiogram, blood pressure measurements and routine blood chemistry in a fasting state. 
Then, they underwent 13N-ammonia positron emission tomography (PET)/computed tomography 
(CT) [17] measurements of myocardial blood flow (MBF) at rest and during vasomotor stress 
performed in a fasting state to assess coronary circulatory function. 
Physical examination revealed normal findings in all applicants and resting electrocardiograms 
showed also no abnormalities. Inclusion criteria were absence of arterial hypertension (blood 
pressure ≤ 140/90 mmHg) or diabetes mellitus (fasting plasma glucose obtained on more than two 
occasions ≤ 126 mg/dL), a non-smoker status and a normal stress-rest perfusion imaging on 
13N-ammonia PET/CT, which widely excluded the presence of flow limiting coronary artery disease 
lesions. The exclusion criteria were any cardiac or vasoactive medication, a history of variant angina, 
a family history of premature coronary artery disease, or clinically manifested cardiovascular or 
systemic diseases. 
Recruited volunteers had a body mass index (BMI, kg/m2) between 20.4 and 51.1. According to 
subject’s BMI, two groups of participants were defined as 1) Non-obese group: 43 non-obese 
individuals with BMI < 30 kg/m2, and 2) Obese group: 29 individuals with BMI ≥ 30 kg/m2. 
2.2. Blood Measurements 
Blood chemistry included plasma triglycerides, total cholesterol, high-density lipoproteins 
(HDL), low-density lipoproteins (LDL), glucose, hemoglobin A1c (HbA1c), insulin and 
high-sensitive C-reactive protein (CRP) concentrations, as previously reported [15,16]. Assessment 
of insulin resistance using the homeostasis model assessment (HOMA) was calculated as fasting 
insulin (mIU/L) × fasting glucose (mg/dL)/22.5, as previously described [17]. 
2.3. Assessment of Myocardial Perfusion with PET/CT 
Myocardial perfusion was determined by 13N-ammonia PET/CT as previously described [17]. 
Myocardial blood flow (MBF, mL/g/min) was assessed at rest, during a cold pressor test (CPT), and 
during hyperemia pharmacologically induced with standard infusion of dipyridamole (140 
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mg/kg/min). The endothelial function was defined as ΔMBF to CPT from rest, and the myocardial 
flow reserve (MFR) was defined as the ratio between MBF during hyperemia and MBF at rest, as 
previously described [16]. 
2.4. Phenotype–Genotype Association Studies 
Polymerase chain reaction (PCR) for the Panx1-400A>C SNP was performed on DNA isolated 
from the blood of each study participant with the following primers (5′-to-3′): forward 
CCGGTGACTGGGTGAAGG, reverse GTCCTGGGCGAGGCTTAC, as previously described [14]. 
Sequencing of PCR products was performed at Fasteris (Geneva, Switzerland). To identify the Panx1 
genotype, all sequences comprising parts of the Panx1 coding region were analyzed using the 
multiple sequence alignment program ClustalW and allele frequency was calculated (i.e., minor 
allele frequency = (WM + 2 × MM)/((WW + WM + MM) × 2)). Minor allele frequency was in 
accordance to the one obtained in an earlier study investigating Panx1-400A>C SNP [14] and the 
distribution of participants of each genotype was in the Hardy–Weinberg equilibrium. Similar to 
earlier studies [14,18], groups were divided in subjects homozygous for the C allele (Panx1-400C, n = 
40) vs. subjects with at least one A allele (Panx1-400A, n = 32). 
2.5. Statistical Analysis 
In tables, results are shown as mean ± standard error of the mean (SEM) or as median 
(interquartile range). Comparisons of means were performed using ANOVA test and post-hoc 
Sidak’s multiple comparison test. Comparisons of medians were performed using non-parametric 
Kruskal–Wallis test and post-hoc Dunn’s multiple comparison test. Comparisons of distributions 
were performed using χ2 test. In figures, results are shown as individual values and as correlation. 
Spearman correlations were performed to examine association between variables. Differences were 
considered statistically significant at values of p < 0.05. Statistical analyses were performed using 
Graphpad Prism 8 software (GraphPad Software, Inc., San Diego, CA, USA). 
3. Results 
3.1. BMI Correlates with Cardiovascular Risk Factors 
The clinical characteristics and laboratory measurements among the groups studied are shown 
in Table 1. Spearman correlations showed that in the full cohort BMI was positively correlated with 
cardiovascular risk factors known to be predictors of CPT-induced ΔMBF and hyperemic MBF 
during dipyridamole stimulation [15] such as serum triglycerides (Figure 1a), glucose (Figure 1b), 
insulin (Figure 1c), HbA1c (Figure 1d) and CRP (Figure 1e). BMI was also positively correlated with 
HOMA as shown in Figure 1f. As expected, BMI was negatively correlated with the serum HDL 
concentration (Figure 1g). There was no correlation between BMI and total cholesterol (Figure 1h) or 
LDL (Figure 1i) serum levels. These results show that, in our cohort of 72 participants, increased BMI 
correlates with cardiovascular risk factors, which is in accordance with previously published studies 
[19–21]. 
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Table 1. Patient characteristics at the time of the inclusion in the study. 
 Full Cohort  
(n = 72) 
Panx1-400C Cohort  
(n = 40) 
Panx1-400A Cohort  
(n = 32) 
p-Value 
Age, years, mean ± SEM 43 ± 1 45 ± 2 42 ± 2 0.63 
Female/male, n (%) 19 (26)/53 (74) 10 (25)/30 (75) 9 (28)/23 (72) 0.89 
Weight (kg), mean ± SEM 90 ± 3 88 ± 3 93 ± 5 0.58 
Height (cm), mean ± SEM 173 ± 1 173 ± 1 173 ± 2 0.98 
BMI (kg/m2), mean ± SEM 30 ± 1 45 ± 2 31 ± 1 0.58 
Heart rate at rest (b.p.m.), 
median (IQR) 
63 (56–70) 63 (55–70) 64 (58–70) 0.97 
SBP at rest (b.p.m.), 
median (IQR) 
119 (110–129) 118 (106–126) 120 (112–132) 0.28 
DBP at rest (b.p.m.), 
median (IQR) 
74 (68–80) 73 (67–80) 76 (68–83) 0.75 
BMI: body mass index; b.p.m: beat per minute; DBP: diastolic blood pressure; IQR: interquartile range; SBP: 
systolic blood pressure; SEM: standard error of the mean. 
 
Figure 1. Body mass index (BMI) associates with cardiovascular risk factors. Spearman correlations 
between BMI and serum triglycerides (a), glucose (b), insulin (c), hemoglobin A1c (HbA1c, (d)), 
C-reactive protein (CRP, (e)), homeostasis model assessment (HOMA) (f), high density-lipoproteins 
(HDL, g), total cholesterol (h), and low-density lipoproteins (LDL) (i), in the full cohort of 
participants (n = 72). 
3.2. BMI, Hemodynamic Parameters, and Panx1-400A>C SNP 
When analyzed separately, the three cohorts did not show differences in the age and the 
proportion of females/males (Table 1). In addition, no differences were found for the height, the 
weight and the BMI (Table 1). Moreover, heart rate, systolic and diastolic blood pressure values at 
rest were not different in the three cohorts (Table 1). Whereas MBF at rest was not affected by BMI 
(data not shown), MBF during CPT, MBF during hyperemia, MFR, and endothelial function were 
negatively correlated with BMI in the full cohort (Figure 2a,d,g,j, respectively). Mean values of all 
these parameters were not different between the full, the Panx1-400C and the Panx1-400A cohorts 
(Table 2). In the Panx1-400C cohort, MBF during CTP (Figure 2b), MBF during hyperemia (Figure 
2e), MFR (Figure 2h) and endothelial function (Figure 2k) were also negatively correlated with BMI 
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whereas no correlation between these hemodynamic parameters and BMI was found in the 
Panx1-400A cohort (Figure 2c,f,i,l). 
 
Figure 2. BMI, hemodynamic parameters and Panx1-400A>C SNP. Spearman correlations between 
body mass index (BMI) and myocardial blood flow (MBF) during cold pressor test (CTP) (a–c), MBF 
during hyperemia (d–f), myocardial flow reserve (MFR) (g–i) and endothelial function (ΔMBF to 
CPT from rest, j–l) in the full cohort ((a,d,g,j) n = 72), the Panx1-400C cohort (b,e,h,k) n = 40) and the 
Panx1-400A cohort (c,f,i,l) n = 32). AA genotype: open circles; AC genotype: closed circles. 
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Table 2. MBF, MFR, and endothelial function measured during 13N-ammonia PET/CT in the three 
cohorts. 
 
Full Cohort  
(n = 72) 
Panx1-400C Cohort  
(n = 40) 
Panx1-400A Cohort  
(n = 32) 
p-Value 
MBF at rest (mL/g/min), median 
(IQR) 
0.72 (0.62–0.78) 0.72 (0.63–0.76) 0.72 (0.62–0.79) 0.99 
MBF during CPT (mL/g/min), 
median (IQR) 
0.85 (0.76–1.04) 0.90 (0.75–1.04) 0.84 (0.76–1.05) 0.99 
MBF during hyperemia 
(mL/g/min), median (IQR) 
2.11 (1.79–2.42) 2.15 (1.84–2.44) 2.08 (1.71–2.32) 0.59 
MFR, median (IQR) 3.03 (2.41–3.43) 3.28 (2.52–3.50) 2.76 (2.38–3.31) 0.40 
ΔMBF to CPT from rest 
(mL/g/min), mean ± SEM 
0.186 ± 0.020 0.179 ± 0.026 0.194 ± 0.030 0.93 
CPT: cold pressor test; CT: computed tomography; IQR: interquartile range; MBF: myocardial blood 
flow; MFR: myocardial flow reserve; ΔMBF to CPT from rest: endothelial function; PET: positron 
emission tomography; SEM: standard error of the mean.  
MBF at rest, MBF during hyperemia and MFR were not different between non-obese (BMI < 30 
kg/m2) and obese (BMI ≥ 30 kg/m2) subjects in the three cohorts and were not affected by the 
Panx1-400A>C SNP (Table 3). During CPT, MBF was reduced in obese subjects in comparison to 
non-obese individuals in the full cohort (Table 3). A similar trend was observed in the Panx1-400C 
cohort but not in the Panx1-400A cohort (Table 3). Mean endothelial function was reduced in obese 
individuals in comparison to non-obese subjects in all three cohorts (Table 3). 
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Table 3. MBF, MFR, and endothelial function measured during 13N-ammonia PET/CT in non-obese and obese subjects from the three cohorts. 
 
Full Cohort  
Non-Obese 
(n = 43) 
Full Cohort 
Obese 
(n = 29) 
p-Value 
Panx1-400C  
Non-Obese  
(n = 25) 
Panx1-400C  
Obese  
(n = 15) 
p-Value 
Panx1-400A  
Non-Obese  
(n = 18) 
Panx1-400A  
Obese  
(n = 14) 
p-Value 
MBF at rest (mL/g/min), median (IQR) 
0.72 
(0.63–0.76) 
0.74 
(0.62–0.84) 
0.35 
0.72 
(0.65–0.75) 
0.69 
(0.57–0.84) 
0.74 
0.70 
(0.60–0.79) 
0.75 
(0.63–0.80) 
0.42 
MBF during CPT (mL/g/min), median (IQR) 
0.93 
(0.81–1.05) 
0.78 
(0.71–0.92) 
<0.01 
0.93 
(0.83–1.04) 
0.76 
(0.70–0.93) 
0.06 
0.92 
(0.78–1.10) 
0.80 
(0.75–0.87) 
0.12 
MBF during hyperemia (mL/g/min), median 
(IQR) 
2.18 
(1.71–2.44) 
2.08 
(1.84–2.31) 
0.43 
2.24 
(1.98–2.47) 
1.95 
(1.44–2.41) 
0.14 
1.94 
(1.59–2.40) 
2.10 
(1.95–2.23) 
0.51 
MFR, median (IQR) 
3.22 
(2.6–3.5) 
2.69 
(2.34–3.42) 
0.16 
3.3 
(2.78–3.58) 
2.64 
(2.22–3.49) 
0.20 
2.92 
(2.36–3.38) 
2.69 
(2.36–3.30) 
0.70 
ΔMBF to CPT from rest (mL/g/min), mean ± SEM 0.246 ± 0.025 0.095 ± 0.023 <0.001 0.238 ± 0.032 0.081 ± 0.033 <0.01 0.259 ± 0.042 0.111 ± 0.035 <0.05 
CPT: cold pressor test; CT: computed tomography; IQR: interquartile range; MBF: myocardial blood flow; MFR: myocardial flow reserve; ΔMBF to CPT from rest: 
endothelial function; PET: positron emission tomography; SEM: standard error of the mean. 
.
Biomolecules 2020, 10, 208 8 of 15 
In non-obese individuals, negative correlations between BMI and MFR and between BMI and 
endothelial function were observed in the full cohort of participants (Figure 3a,d, respectively). 
Interestingly, such correlations for non-obese subjects were also observed in the Panx1-400C cohort 
(Figure 3b,e) but not in the Panx1-400A cohort (Figure 3c,f). No correlation between BMI and MFR or 
between BMI and endothelial function was observed for obese subjects in the three cohorts (Figure 3). 
Altogether, these results bring out that the Panx1-400A>C SNP does not change by itself 
hemodynamic parameters but that the impairment of these hemodynamic parameters is correlated 
with increased BMI in Panx1-400C subjects but not in Panx1-400A individuals. Moreover, this effect 
of the Panx1-400C SNP on the impairment of these hemodynamic parameters with increasing 
bodyweight is only present in non-obese subjects. 
 
Figure 3. Correlation between BMI and MFR or endothelial function. Spearman correlations between 
body mass index (BMI) and myocardial flow reserve (MFR, (a–c)) or endothelial function (∆MBF to 
CPT from rest, (d–f)) in non-obese and obese subjects in the full cohort ((a,d) n = 43 and 29, 
respectively), the Panx1-400C cohort ((b,e) n = 25 and 15, respectively) and the Panx1-400A cohort 
((c,f) n = 18 and 14, respectively). AA genotype: open circles; AC genotype: closed circles. 
3.3. Correlation between BMI and Cardiovascular Risk Factors in Non-obese and Obese Subjects 
In non-obese individuals, serum triglycerides and insulin as well as HOMA were positively 
correlated with increasing BMI in the Panx1-400C cohort (Figure 4a,c,e respectively), but not in the 
Panx1-400A cohort (Figure 4b,d,f, respectively). In both cohorts, no correlation was observed 
between increasing BMI and serum glucose, HbA1c, CRP, or HDL concentrations for non-obese 
subjects (data not shown). For obese subjects, no correlation was shown between increasing BMI and 
the various cardiovascular risk factors tested (data not shown). 
Here, we show that in non-obese subjects, Panx1-400C SNP favors positive correlation between 
BMI and triglyceride levels, insulin levels and HOMA, which is not the case for non-obese 
Panx1-400A individuals. 
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Figure 4. Correlation between BMI and cardiovascular risk factors in non-obese subjects. Spearman 
correlations in non-obese subjects between body mass index (BMI) and serum triglycerides (a,b), 
insulin (c,d) and HOMA (e,f) in the Panx1-400C cohort ((a,c,e) n = 25) and the Panx1-400A cohort 
((b,d,f) n = 18). AA genotype: open circles; AC genotype: closed circles. 
3.4. Correlation Between Hemodynamic Parameters and Cardiovascular Risk Factors in Non-Obese Subjects 
Negative correlations between MFR and serum triglycerides, insulin or HOMA were observed 
in non-obese subjects from the Panx1-400C cohort (Figure 5a,c,e, respectively). These correlations 
were completely absent in non-obese subjects from the Panx1-400A cohort (Figure 5b,d,f). Moreover, 
the slopes of the correlation between MFR and these cardiovascular risk factors in non-obese 
individuals were significantly different between the Panx1-400C and the Panx1-400A cohorts 
(Figure 5a vs. 5b, 5c vs. 5d, and 5e vs. 5f). 
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Figure 5. Correlation between MFR and cardiovascular risk factors in non-obese subjects. Spearman 
correlations in non-obese individuals between myocardial flow reserve (MFR) and serum 
triglycerides (a,b), insulin (c,d), and HOMA (e,f) in the Panx1-400C cohort ((a,c,e) n = 25) and the 
Panx1-400A cohort ((b,d,f) n = 18). AA genotype: open circles; AC genotype: closed circles. * p < 0.05; 
** p < 0.01: slope of non-obese subjects in the Panx1-400C cohort vs. slope of non-obese subjects in the 
Panx1-400A cohort. 
Finally, no correlation was found between endothelial function and serum triglycerides (Figure 
6a,b), insulin (Figure 6c,d) or HOMA (Figure 6e,f) in non-obese subjects from the Panx1-400C cohort 
(Figure 6a,c,e) or the Panx1-400A cohort (Figure 6b,d,f). 
Altogether, our results demonstrate that for non-obese Panx1-400C subjects, elevation in 
triglyceride and insulin concentrations as well as increased HOMA promote endothelial dysfunction 
and a reduction in MFR, effects that are absent or even slightly inverted in non-obese Panx1-400A 
subjects. 
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Figure 6. Correlation between endothelial function and cardiovascular risk factors in non-obese 
subjects. Spearman correlations in non-obese subjects between endothelial function and serum 
triglycerides (a,b), insulin (c,d), and HOMA (e,f) in the Panx1-400C cohort ((a,c,e) n = 25) and the 
Panx1-400A cohort ((b,d,f) n = 18). AA genotype: open circles; AC genotype: closed circles. 
4. Discussion 
The present study shows for the first time an implication of the Panx1-A400C SNP in 
endothelial dysfunction and reduced myocardial perfusion under stress. Panx1 channels are 
involved in physiological and pathological processes ascribed to ATP release such as the regulation 
of vasomotor function, glucose metabolism, leukocyte recruitment, adipogenic progenitor cell 
differentiation, ischemia–reperfusion injury or pain [22–29]. This multiplicity of functions involves 
different mechanisms of Panx1 channel activation including elevated extracellular potassium, 
stretch, Src family kinase-mediated phosphorylation, or cleavage of the C-terminal tail by caspases 
[8]. The SNP studied in the present study has been demonstrated to affect Panx1 channel 
functionality [14]. The base pair modification A400C in the Panx1 gene results in an amino acid 
substitution at position 5 in the cytoplasmic N-terminal part of the protein. This shift from an 
uncharged Glutamine to a positively charged Histidine may induce conformational changes in the 
pore formed by the hexameric assembly of Panx1 proteins, leading to enhanced ATP release. Indeed, 
Panx1-deficient CHO cells transfected with Panx1-400C displayed increased basal and stimulated 
ATP release compared to cells transfected with Panx1-400A [14]. The effects of other N-terminal 
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modifications on Panx1 channel opening have been demonstrated by patch clamp experiments 
showing that a weak voltage-dependent activity is drastically increased when a Glycine–Serine 
amino acid pair is inserted after the first Methionine [30]. 
The Panx1-A400C SNP has previously been described as potential modifier of 
atherothrombosis [14]. Indeed, the gain-of-function channel variant (Panx1-400C) was associated 
with enhanced collagen-induced platelet reactivity in a cohort of 96 healthy volunteers and was also 
identified in cohorts of patients with a hyper- or hypo-reactive platelet phenotype with the 
Panx1-400C variant being more prevalent in the hyper-reactive patients. Here, we aimed to evaluate 
the potential implication of this Panx1 genetic variant in endothelial dysfunction and myocardial 
perfusion in obese and non-obese individuals. Overweight and obesity are conditions known to alter 
endothelial cell functionality [1] through mechanisms such as insulin resistance, increased serum 
cholesterol and LDL levels, pro-inflammatory adipokine release and elevated free fatty acids (FFAs) 
production by adipose tissue [31]. In accordance, we showed in our full cohort of 72 study 
participants that increased BMI was positively correlated with serum triglycerides, glucose, insulin, 
HbA1c and CRP levels, and with insulin resistance (HOMA) (Figure 1). Moreover, increased BMI 
was negatively correlated with myocardial perfusion under stress and with endothelial function 
(Figure 2). These negative correlations were also found in a subgroup of non-obese individuals but 
were lost in obese subjects (Figure 3). Interestingly, similar negative correlations were observed in 
Panx1-400C subjects but not in Panx1-400A individuals (Figures 2 and 3). In Panx1-400C non-obese 
subjects, BMI was positively correlated with triglycerides and insulin levels and with HOMA 
(Figure 4). Such positive correlations were absent in Panx1-400A non-obese individuals. Elevated 
triglyceride levels as well as increased glucose and insulin concentrations are known to induce 
endothelial dysfunction by increasing inflammation, apoptosis, and mainly by increasing reactive 
oxygen species production [32–34]. The latter processes have all three been shown to be affected by 
Panx1 expression or Panx1 channel functionality. For instance, in atherosclerosis-prone mice fed a 
high cholesterol diet, ubiquitous Panx1 deletion was shown to reduce serum triglyceride and FFA 
levels [12]. This effect was attributed to impairment of lymphatic function in Panx1-deficient mice, 
which is affecting lipid uptake as demonstrated with an oral lipid tolerance test. Moreover, 
experiments performed in rat INS-1E beta-cells showed that Panx1 channel activation by chronic 
fructose exposure potentiated glucose-stimulated insulin secretion [29]. In addition, Panx1 channel 
activity appeared to contribute to the control of metabolic homeostasis by regulating 
insulin-stimulated glucose uptake in adipocytes [24]. Finally, mice with ubiquitous Panx1 deletion 
have increased fat mass and reduced lean mass [12,13]. This increase in body adiposity is mainly due 
to larger volumes of subcutaneous and visceral adipose tissues [12] and results in increased glucose 
and insulin levels [13]. Altogether, these observations suggest strong links between Panx1 channel 
functionality, metabolism and endothelial function. Our data further strengthen this hypothesis as 
we found that myocardial perfusion under stress was negatively correlated with BMI (Figure 3), 
serum triglycerides, insulin levels and HOMA (Figure 5) in Panx1-400C non-obese subjects 
expressing the gain-of-function channel, while no correlation between these parameters was found 
in the non-obese Panx1-400A cohort. The reason that the effect of the gain-of-function channel is lost 
in obese subjects might be an exacerbated increase in metabolic and cardiovascular risk factors in 
this sub-population. Altogether, these results suggest that the Panx1-A400C SNP by itself does not 
influence hemodynamic parameters, but that the impairment of hemodynamic function is correlated 
with increased BMI in Panx1-400C subjects but not in Panx1-400A individuals. Many studies 
indicate that the risk to develop endothelial dysfunction increases with the number of risk factors 
co-existing in an individual [35,36]. This association between increased BMI and reduced MFR in the 
non-obese subjects of the Panx1-400C cohort could be attributed to increased risk factors for 
endothelial dysfunction. Although no significant correlation between endothelial function and 
serum triglycerides, insulin and HOMA were observed in Panx1-400C individuals, it is noteworthy 
that a similar trend to the one obtained for myocardial perfusion under stress was found (Figure 6). 
Although the main limitation of the present study is the small size of the cohorts, to the best of our 
knowledge, this study is the first one uniquely linking the Panx1 SNP, encoding for a 
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gain-of-function ATP release channel, BMI, cardiovascular risk factors, endothelial function and 
myocardial perfusion. The prevalent Panx1-400C SNP thus drives the relation between impaired 
hemodynamic parameters, increased occurrence of cardiovascular risk factors and increased BMI in 
the general population, which may be taken into account in future investigations. 
5. Conclusion 
Our data show that the Panx1-400C SNP predisposes for the development of endothelial 
dysfunction and reduced myocardial perfusion during stress (induced by CPT or 
dipyridamole-induced hyperemia) with increasing BMI in non-obese subjects. 
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